Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy: A Cost-Minimization Analysis

Author： Ravasio Roberto   Ortega Cinzia   Sabbatini Roberto   Porta Camillo  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.31, Iss.7, 2011-07, pp. : 507-517

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

First-line sunitinib cost-effective alternative to interferon-α in renal cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 561, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma

By Chabot Isabelle   Rocchi Angela  

Value in Health, Vol. 13, Iss. 6, 2010-09 ,pp. : 837-845

Blackwell Publishing

Access to resources Recommend Favorite

Sunitinib cost-effective alternative to interferon-α in renal cancer

By  

Inpharma, Vol. 1, Iss. 1654, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Interferon-α plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: A pilot study

By Amato Robert   Rawat Anish  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 171-175

Springer Publishing Company

Access to resources Recommend Favorite

Roche's bevacizumab [Avastin] has been approved as a first-line treatment for advanced renal cell cancer in the EU

By  

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 27-27

Adis International

Access to resources Recommend Favorite